Pulsatile Pressure Waveform to Confirm Correct Placement of the Epidural in Laboring Patients

Sponsor
Lawson Health Research Institute (Other)
Overall Status
Terminated
CT.gov ID
NCT02395796
Collaborator
(none)
15
1
1
7.1
2.1

Study Details

Study Description

Brief Summary

Epidural analgesia is highly effective for labor pain relief and is widely chosen by pregnant patients. However, placement of the epidural needle can be challenging in pregnant patients due to lax tissue ligaments and edema so that the traditional loss of resistance method (LOR) used to find the space may be subtle leading to retries which may delay onset of analgesia as well as increase the risk of complications. The ability to transduce a pulsatile pressure waveform from epidural needles placed in non-laboring patients correlates highly with successful placement of the epidural needle. We wish to evaluate the efficacy of obtaining a pulsatile pressure waveform with correct epidural needle placement in laboring women.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Epidural Pressure Waveform
N/A

Detailed Description

Patients requesting epidural labor analgesia will be eligible for recruitment. After written informed consent is obtained, placement of monitors and aseptic technique, the 17G epidural needle will be placed using the loss of resistance (LOR) technique to air or saline at the lumbar level chosen by the anesthesiologist. When LOR occurs, the needle will then be filled with 2 mL NaCl 0.9% from that syringe and the pressure monitoring accessory will be connected to the needle. The second investigator will then connect the high pressure tubing to the acessory without touching it, and the pressure will be zeroed at level of the needle insertion. Pressure will then be transduced and the waveform, recorded. An epidural catheter (SIMS Portex) will then be passed through the needle and advanced 5 cm beyond the tip of the epidural needle. After securing the epidural catheter in place, the patient will be placed on the lateral position. The catheter will then be filled NaCl 0.9% from a syringe and a high-pressure tubing extension leveled at the spine level will be connected to the catheter and the pressure will be transduced and recorded. Data recorded will include 2 parameters: 1) The presence or absence of a pulsatile waveform, and 2) The actual pressure read at the epidural space, in mmHg. Those readings will be obtained in 2 distinct moments: at a " rest" state, meaning during an interval between contractions, and at an "active" state, during the first contraction after the epidural catheter is placed. A test dose of 3 mL of 2% lidocaine with epinephrine1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Efficacy of the Presence of a Pulsatile Pressure Waveform to Confirm Correct Placement of the Epidural Needle and Catheter in Laboring Pregnant Patients: a Feasibility Study
Study Start Date :
Jul 1, 2015
Actual Primary Completion Date :
Feb 1, 2016
Actual Study Completion Date :
Feb 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Epidural Pressure Waveform

Study Population: Term pregnancy in labour 18 years of age or older.

Procedure: Epidural Pressure Waveform
When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.

Outcome Measures

Primary Outcome Measures

  1. Epidural Needle Insertion Success [30 min after loading dose]

    Presence of a pulsatile pressure waveform at the epidural needle as a good predictor of a successful epidural block 30 min after local anesthetic injection

Secondary Outcome Measures

  1. Epidural Pressure in mmHg [5 min after epidural needle insertion]

    Epidural pressures during uterine contractions and in-between contractions in mmHg

  2. Epidural Waveform at the Catheter [Immediately after epidural catheter insertion]

    Presence or absence of an epidural waveform measured through the epidural catheter right after insertion

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Female Patients

  • ASA I-III

  • Term Pregnancy (>37 weeks)

  • 18 years or older

  • Early Labour (<6 cm of cervical dilation)

  • BMI<40

Exclusion Criteria:
  • Any contraindication to epidural analgesia placement (coagulopathy, sepsis, infection at site, increased ICP, hypovolemia, unstable ischemic heart disease, unstable neurologic disease, severe aortic stenosis, prior spinal surgery, LA allergy)

  • Serious concern for maternal or fetal wellfare.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Victoria Hospital- LHSC London Ontario Canada N6A 5A5

Sponsors and Collaborators

  • Lawson Health Research Institute

Investigators

  • Principal Investigator: Indu Singh, MD, FRCPC, University of Western Ontario, Schulich School of Medicine, Department of Anesthesia

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ilana Sebbag, Principal Investigator, Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT02395796
Other Study ID Numbers:
  • 106323
First Posted:
Mar 24, 2015
Last Update Posted:
Feb 25, 2016
Last Verified:
Feb 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Ilana Sebbag, Principal Investigator, Lawson Health Research Institute

Study Results

No Results Posted as of Feb 25, 2016